简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
Abstract:(Reuters) – Merck & Co expects a research-and-development charge of about $10.3 billion, or $4 per share, this year as the drugmaker accounts its deal for Prometheus Biosciences Inc as an asset acquisition, CFO Caroline Litchfield said.
(Reuters) – Merck & Co expects a research-and-development charge of about $10.3 billion, or $4 per share, this year as the drugmaker accounts its deal for Prometheus Biosciences Inc as an asset acquisition, CFO Caroline Litchfield said.
The deal is expected to hit Mercks profit by 25 cents per share in the first 12 months, Litchfield said in an investor conference call on Monday.
The deal is expected to close in the third quarter.
Merck on Sunday agreed to buy Prometheus for about $10.8 billion to build up its presence in immunology. Net of Prometheus cash balance, the price paid comes to $10.3 billion.
(Reporting by Raghav Mahobe and Leroy Leo in Bengaluru; Editing by Devika Syammnath)
Disclaimer:
The views in this article only represent the author's personal views, and do not constitute investment advice on this platform. This platform does not guarantee the accuracy, completeness and timeliness of the information in the article, and will not be liable for any loss caused by the use of or reliance on the information in the article.